Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK2GZX)

Drug Name
Avapritinib Drug Info
Synonyms
1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal stromal tumour 2B5B Approved [1]
Mast cell leukaemia 2A21.00 Phase 1 [2]
Systemic mastocytosis 2A21.0 Phase 1 [3]
Cross-matching ID
PubChem CID
118023034
CAS Number
CAS 1703793-34-3
TTD Drug ID
DMK2GZX
ACDINA Drug ID
D01518

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [4]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [5]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [6]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [8]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [12]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
7 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
8 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
9 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
10 National Cancer Institute Drug Dictionary (drug id 452042).
11 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
12 Clinical pipeline report, company report or official report of MedImmune (2011).
13 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.